Literature DB >> 19072910

Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders.

Dimitra Terzi1, Venetia Zachariou.   

Abstract

Over the last few years, a large number of preclinical and clinical studies have demonstrated the potential of gene therapy applications using adeno-associated viral (AAV) vectors. Gene transfer via AAV vectors has been particularly successful for the treatment or adjunct therapy of several CNS disorders. The present review summarizes the progress on AAV gene delivery models for three different CNS disorders. In particular, we discuss advances in AAV-mediated gene transfer strategies in animal models of Parkinson's disease, Alzheimer's disease and spinal cord trauma and summarize the results from the first clinical studies using AAV systems.

Entities:  

Mesh:

Year:  2008        PMID: 19072910     DOI: 10.1002/biot.200800284

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  12 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

Review 2.  Genetic approaches to investigate the role of CREB in neuronal plasticity and memory.

Authors:  Angel Barco; Hélène Marie
Journal:  Mol Neurobiol       Date:  2011-09-23       Impact factor: 5.590

3.  The assessment of adeno-associated vectors as potential intrinsic treatments for brainstem axon regeneration.

Authors:  Ryan R Williams; Damien D Pearse; Patrick A Tresco; Mary Bartlett Bunge
Journal:  J Gene Med       Date:  2012-01       Impact factor: 4.565

4.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

5.  An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector.

Authors:  Marijke W A de Backer; Carlos P Fitzsimons; Maike A D Brans; Mieneke C M Luijendijk; Keith M Garner; Erno Vreugdenhil; Roger A H Adan
Journal:  BMC Neurosci       Date:  2010-07-13       Impact factor: 3.288

6.  Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats.

Authors:  Wenjing Zhang; Yang Wang; Shuyun Dong; Rajarshi Choudhury; Yongfeng Jin; Zefeng Wang
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

7.  Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.

Authors:  Tarja Malm; Jari Koistinaho; Katja Kanninen
Journal:  Int J Alzheimers Dis       Date:  2011-10-30

8.  Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.

Authors:  Sang-Min Oh; Mi-Yoon Chang; Jae-Jin Song; Yong-Hee Rhee; Eun-Hye Joe; Hyun-Seob Lee; Sang-Hoon Yi; Sang-Hun Lee
Journal:  EMBO Mol Med       Date:  2015-05       Impact factor: 12.137

9.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

10.  Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice.

Authors:  Akira Machida; Hiroya Kuwahara; Azat Mayra; Takayuki Kubodera; Takashi Hirai; Fumiko Sunaga; Mio Tajiri; Yukihiko Hirai; Takashi Shimada; Hidehiro Mizusawa; Takanori Yokota
Journal:  Mol Pain       Date:  2013-07-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.